STOCK TITAN

Tauriga Sciences Inc. Fully Repays its $135,000 Inventory Factoring Credit Facility, Entered Into on October 6, 2020

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Tauriga Sciences, Inc. (OTCQB: TAUG) has fully repaid its $135,000 Non-Convertible inventory factoring credit facility a month early, demonstrating improved financial health. The repayment included five installments of $21,214.29 and a final installment of $42,428.58. Initially structured with a 10% annual interest rate and a grace period, the repayment signifies the company's growing retail business and fiscal responsibility.

Positive
  • Full repayment of $135,000 credit facility enhances financial stability.
  • Repayment completed a month ahead of schedule, indicating strong retail performance.
Negative
  • None.


The Company Repaid This Facility Entirely in Cash: 5 Equal Installments of $21,214.29 and a Final Installment of $42,428.58

NEW YORK, NY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has fully repaid and retired its $135,000 Non-Convertible inventory factoring credit facility (the “Facility”), entered into with an institutional investor, on October 6, 2020.  The Company repaid this Facility entirely in cash: for 5 equal installment payments of $21,214.29 and a final installment of $42,428.58.  Due to the Company’s improved retail business, it decided to retire this Facility a month early. 
           
This $135,000 in factoring capital was structured as a non-convertible promissory note (interest bearing: 10.00% per annum), with a built in 6-month grace period.  Repayment of this loan, contractually, was to occur in 7 equal monthly payments of $21,214.29 (Repayment Period: April 5, 2021 thru October 5, 2021).

Link to Press Release from October 6, 2020  

https://www.globenewswire.com/news-release/2020/10/06/2104547/0/en/Tauriga-Sciences-Inc-Secures-135-000-in-Inventory-Factoring-Capital-to-Support-its-Accelerating-Revenue-Growth.html

The Broker Dealer, Moody Capital, acted as the Placement Agent for this transaction.

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

The Company is headquartered in Wappingers Falls, New York.  In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

4 Nancy Court, Suite 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @sethsms47

Twitter: @SethMShaw

Corp. Website:   www.tauriga.com

E-Commerce Website:  www.taurigum.com


FAQ

What is the significance of Tauriga Sciences repaying its credit facility?

The early repayment of the $135,000 credit facility highlights Tauriga's improved financial health and strong retail business performance.

How did Tauriga Sciences repay its credit facility?

Tauriga repaid the facility in five installments of $21,214.29 and a final installment of $42,428.58, totaling $135,000.

What was the interest rate on Tauriga's credit facility?

The non-convertible credit facility had an interest rate of 10.00% per annum.

When was the credit facility entered into by Tauriga Sciences?

The credit facility was entered into on October 6, 2020.

What does the repayment of the credit facility indicate about Tauriga Sciences?

The repayment indicates that Tauriga Sciences is experiencing improved retail business operations and financial responsibility.

TAURIGA SCIENCES INC

OTC:TAUG

TAUG Rankings

TAUG Latest News

TAUG Stock Data

299
293.33M
0.02%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Wappingers Falls